<DOC>
	<DOCNO>NCT01093612</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , copper Cu 64-DOTA-trastuzumab-labeled PET , may help doctor plan good treatment PURPOSE : This pilot trial study copper Cu 64-tetra-azacyclododecanetetra-acetic acid ( DOTA ) -trastuzumab-labeled positron emission tomography ( PET ) woman human epidermal growth factor receptor 2 ( HER2 ) -positive breast cancer .</brief_summary>
	<brief_title>Positron Emission Tomography Women With Advanced HER2-Positive Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine dose pre-administered cold antibody optimize image quality 64Cu-DOTA-trastuzumab PET without increase radiation dose heart woman metastatic HER2 positive breast cancer . II . Determine whether tumor uptake 64Cu-DOTA-trastuzumab PET correlate tumor expression HER2 woman metastatic disease . III . Perform exploratory analysis relationship uptake 64Cu-DOTA-trastuzumab PET , HER2 overexpression , inactivation PI3K/Akt pathway . OUTLINE : This part one dose-determining study follow part two study . PART ONE : Patients randomize 1 3 dose level . Patients undergo PET scan 24-48 hour injection 64 Cu-DOTA-trastuzumab . PART TWO : Patients undergo PET scan 24-48 hour injection 64 Cu-DOTA-trastuzumab optimal dose determine part one study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Copper</mesh_term>
	<criteria>Eligibility Part I ( Determination cold dose ) Participants must woman histological confirmation metastatic invasive breast cancer metastasize outside region primary tumor axilla . Biopsy must obtain within 28 day prior study . Patients must metastatic disease lung , liver , softtissue bone qualify study ( one site permissible ) . At least 1 nonhepatic site metastasis great equal 2 cm mean diameter must identify addition site biopsied . The cancer must express HER2 determine IHC FISH . Patients may receive trastuzumab adjuvant , neoadjuvant , metastatic setting , receive drug within prior 2 month . Participants must normal cardiac ejection fraction . Eligibility Part 2 ( correlation HER2 expression PET uptake ) Participants must woman histological confirmation metastatic invasive breast cancer metastasize outside region primary tumor axilla . Biopsy must obtain within 28 day prior study . Patients must metastatic disease lung , liver , softtissue bone qualify study ( one site permissible ) . At least 1 nonhepatic site metastasis site great equal 2 cm mean diameter must identify addition site biopsied . Participants HER2 1+ , 2+ 3+ IHC eligible . Patients may receive trastuzumab adjuvant , neoadjuvant , metastatic setting , receive drug within prior 2 month . Participants must normal cardiac ejection fraction . Ineligibility Participants receive trastuzumab within prior 2 month Participants consider candidate trastuzumab Metastatic disease single site No metastatic site great equal 2 cm Concurrent malignancy skin cancer Inability provide inform consent Participants pregnant</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HER2-positive breast cancer</keyword>
</DOC>